Showing results (681-690 of 1,191) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|November 4, 2006
Sample size calculations for clinical studies allowing for uncertainty about the varianceSteven A Julious, Roger J OwenPharmaceutical Statistics|January 24, 2007
Analysis of progression-free survival in oncology trials: some common statistical issuesKevin J CarrollPharmaceutical Statistics|December 14, 2022
Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ETYunqi Zhao, Rachael Liu, Kentaro TakedaPharmaceutical Statistics|November 23, 2022
Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive powerQingyang Liu, Guanyu Hu, Binqi Ye, et al.Pharmaceutical Statistics|November 16, 2019
Cancer immunotherapy trial design with delayed treatment effectJianrong Wu, Jing WeiPharmaceutical Statistics|November 16, 2019
Empowering phase II clinical trials to reduce phase III failuresDaniele De MartiniPharmaceutical Statistics|July 16, 2021
A unified approach for evaluating the prediction of treatment effect across different types of endpointsYongming Qu, So Young Park, Qiwei Wu, et al.Pharmaceutical Statistics|December 7, 2020
Early stopping in seamless phase I/II clinical trialsNoor M Khan, M Iftakhar AlamPharmaceutical Statistics|December 15, 2012
On the practical application of mixed effects models for repeated measures to clinical trial dataScott W Andersen, Brian A MillenPageof 120